After a rocky decades-long journey, Takeda’s CMV drug gets FDA OK
After a wild two-decade ride, the FDA has approved Takeda’s antiviral maribavir — now marketed as Livtencity — for cytomegalovirus, one of the most common viral infections experienced by transplant patients.
Takeda picked up maribavir a couple years ago in its $62 billion Shire buyout, at which point the drug had already failed a Phase III trial and changed hands a few times. But on Tuesday, Takeda touted a regulatory win in patients 12 years and older, marking the second approval this year for one of the company’s new molecular entities.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.